Introduction to Field Medical's Funding Success
Field Medical, Inc. has recently announced the successful closure of a $35 million Series B financing round aimed at enhancing its innovative FieldForce™ Pulled Field Ablation Platform. This important milestone marks the company's commitment to advancing cardiac ablation technologies and positions it at the forefront of treatment options for patients suffering from ventricular tachycardia (VT).
Driving Forces Behind the Financing
The financing round was co-led by BioStar Capital and Cue Growth, prominent investors in the medical technology sector. Their involvement signifies a strong belief in the potential of Field Medical's technology to revolutionize the treatment of complex cardiac conditions. The funds will primarily support the initiation of the pivotal VERITAS trial, aimed at evaluating the efficacy of the FieldForce Ablation System.
Strengthening Clinical Capabilities
With this latest influx of capital, Field Medical plans to not only advance its clinical trials but also expand its regulatory capabilities. The company’s recent pilot data presentation at an influential cardiac meeting showcased promising results, further attracting the interest of institutional investors and reinforcing the company's strategic direction.
Insights from Leadership
Steven Mickelsen, MD, the founder and CEO of Field Medical, emphasized the urgency and necessity of addressing the underpenetrated ventricular tachycardia market. He indicated that the clinical demand is reminiscent of the early days in the atrial fibrillation (AF) market, where medical professionals lacked effective tools. Field Medical is poised to leverage this opportunity with their next-generation therapy which focuses on speed and precision.
Transformative Technology at Work
BioStar Capital’s founder, Louis Cannon, expressed strong confidence in Field Medical's innovative approach. He stated that the company's physician-led team provides invaluable insights, particularly in developing effective tools for VT treatment. The FieldForce platform is designed to tackle significant challenges in cardiology, positioning the company as a leader in medical innovation.
Insights into the Board Leadership
In alignment with its ambitious growth trajectory, Field Medical has announced changes to its Board of Directors. The updated board, which includes industry leaders and seasoned professionals, is well-equipped to guide the company through its next phase of growth.
- Steven Mickelsen, MD – Founder and CEO, with a wealth of experience as an electrophysiologist and inventor of cutting-edge ablation technologies.
- Mark Wisniewski – CFO of Enterra Medical, bringing expertise in medtech operations and mergers and acquisitions.
- Marlou Janssen – An experienced executive with a robust background in commercial and clinical strategy.
- Alexei Mlodinow, MD, MBA – A seasoned entrepreneur focused on medtech innovation.
- Ben Cannon – As a founding partner of Cue Growth, he enhances governance and drives performance in scaling the company.
Field Medical: Innovating Cardiac Care
Founded in 2022, Field Medical continues its mission to reshape cardiac care using pulsed field ablation technologies. Headed by Dr. Steven Mickelsen, the FieldForce Ablation System integrates advanced catheter design with proprietary energy methods to enable efficient and effective treatments. The company received Breakthrough Device Designation and participation in the FDA TAP Pilot Program, demonstrating its commitment to innovation in VT treatment.
Field Medical remains dedicated to advancing its technology and expanding its clinical focus, which could change the landscape of arrhythmia treatments moving forward. The company invites those interested to explore their educational resources online and stay engaged with their groundbreaking advancements.
Frequently Asked Questions
What is the purpose of the recent Series B funding for Field Medical?
The funding aims to support the initiation of the pivotal VERITAS trial and expand capabilities in cardiac ablation technology.
Who led the financing for Field Medical?
BioStar Capital and Cue Growth co-led the financing round, reflecting confidence in Field Medical's potential.
What technology does Field Medical specialize in?
Field Medical specializes in pulsed field ablation (PFA) technologies designed for treating complex cardiac arrhythmias.
How does the FieldForce Ablation System work?
The system combines advanced catheter design with proprietary energy to enable targeted ablation quickly and efficiently.
What is the significance of the Board of Directors update?
The updates reflect Field Medical's growth and strategic focus, enhancing governance with industry leaders to guide the company.
